This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CETi-1

Celldex Therapeutics, Inc.

Drug Names(s): CETi-1

Description: AVANT's cholesterol management agent, CETi-1, is designed to raise serum HDL (high-density lipoprotein) cholesterol levels by blocking the transfer of cholesterol from HDL to LDL (low-density lipoprotein). CETi-1 induces antibodies against a portion of CETP, the serum protein responsible for this transfer. HDL (often referred to as 'good' cholesterol) acts to protect against atherosclerosis while LDL (often referred to as 'bad' cholesterol) acts to promote atherosclerosis.


CETi-1 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug